🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

📑 Predicting long-term survival among patients with #HCC❕ ⭐️ MILES Score: A novel score using objective data to predict survival in HCC patients pre-liver transplant journals.lww.com/hepcomm/fullte…

Original Article Targeting protein hyperSUMOylation halts cholangiocarcinoma progression by impairing cancer cell viability and tumor-stroma crosstalk Olaizola et al. #LiverX tinyurl.com/5dmn7yw3

Our review on MetALD is out! It summarizes current concepts on an entity we knew was there but somewhat neglected it. Honored to work with my friends and colleagues Juan Pablo (JP) Arab, MD  Luis Antonio Díaz, MD Rohit Loomba Ramon Bataller Naim Alkhouri Mazen Noureddin, MD, MHSc Francisco Idalsoaga MD

Thrilled to share our most recent publication. Appreciate Dr Winston Dunn, Naim Alkhouri and my mentor Dr Abdelmalek Manal Abdelmalek for giving me the opportunity to participate in this huge study Machine learning approach for fibrosis prediction in MASLD F2 and higher

Today is the #WorldLiverDay This year the theme is #Foodismedicine because also a good nutrition take care about our liver #LiverHealthMatters

Breaking! Phase 3 ESSENCE trial results just out: Semaglutide 2.4 mg showed significant improvements for adults with #MASH-63% achieved resolution of steatohepatitis with no worsening of fibrosis vs. 34% on placebo at 72 weeks. #LiverHealth nejm.org/doi/full/10.10… NEJM

Very important paper led by Arun J. Sanyal In patients with MASH and F2-3, once-weekly semaglutide at a dose of 2.4 mg improved liver histologic results. The findings in fibrosis are very interesting and encouraging, let’s go now for ALD! #LiverTwitter #LiverX

Me sumo a la recomendacion de esta interesante actividad de #ALEH con dos grandes expositores

Honored to participate in this important effort. Rohit Loomba

#EASLCongress General Session 2 Pedro Rodrigues presents a novel 3-in-1 blood metabolomic test for the early diagnosis & risk stratification of PSC & CCA 👏🏼👏🏼👏🏼 Jesus Bañales EASLnews

No se pierdan el Webinar ALEH + Asociación Española para el Estudio del Hígado el 📅 Jueves 15 mayo 2025. Tenemos 2 grandes speakers Sebastian Marciano y Juan Turnes que entregarán estrategias para escribir abstracts (incluyendo IA 🤖). Inscripciones ✅: eventual-latam.us12.list-manage.com/track/click?u=… AASLD EASL Education #LiverTwitter

Impressive work

Very important paper to get a step closer to incorporating genetic polymorphisms for precision medicine #LiverTwitter #LiverX

It is a privilege to have Dr. Díaz as a speaker for our Seminar Series... Don't miss it! #LiverTwitter #LiverX AASLD EASLnews ALEH

Absolutely thrilled to meet Dr. Michael Trauner and hear his insights on emerging therapies for PSC. Grateful for the chance to have a quick chat with the bile expert himself! Check out the latest research on PSC management in the pictures below. Thank you VCU Stravitz-Sanyal Institute for Liver Disease

Honored to be part of this great work. Congratulations to Luis Antonio Díaz, MD and the entire team led by Veeral Ajmera, for this achievement. Rohit Loomba, UCSD Gastroenterology, Juan Pablo (JP) Arab, MD 

Elliot Tapper Umair. M Juan Pablo (JP) Arab, MD  Marco Arrese, MD Thank you for your words Elliot Tapper! The credit goes to all our mentors Marco Arrese, MD and the continued support from Facultad Medicina UC Dr. Alejandro Soza 

Join us May 28 for a presentation by Luis Antonio Díaz, MD, of UC San Diego, on “MetALD: Bridging the Gap Between Metabolic Dysfunction and Alcohol-Associated Liver Disease.” Register at bit.ly/3GKSB5O #livertwitter

New contribution of this great research group from the Basque country!!

Always proud of Luis Antonio Díaz, MD for his great achievements! A real rising star of world hepatology